Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLATIRAMER Cause Bladder transitional cell carcinoma? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Bladder transitional cell carcinoma have been filed in association with GLATIRAMER (GLATIRAMER ACETATE). This represents 0.0% of all adverse event reports for GLATIRAMER.

5
Reports of Bladder transitional cell carcinoma with GLATIRAMER
0.0%
of all GLATIRAMER reports
0
Deaths
5
Hospitalizations

How Dangerous Is Bladder transitional cell carcinoma From GLATIRAMER?

Of the 5 reports, 5 (100.0%) required hospitalization.

Is Bladder transitional cell carcinoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GLATIRAMER. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does GLATIRAMER Cause?

Injection site pain (5,003) Multiple sclerosis relapse (3,695) Drug ineffective (3,321) Injection site reaction (3,317) Multiple sclerosis (2,596) Injection site erythema (2,560) Fatigue (2,408) Dyspnoea (2,364) Injection site mass (2,172) Injection site swelling (1,836)

What Other Drugs Cause Bladder transitional cell carcinoma?

PIOGLITAZONE (398) ADALIMUMAB (96) METHOTREXATE (95) RITUXIMAB (74) TOCILIZUMAB (68) INFLIXIMAB (63) SULFASALAZINE (55) HYDROXYCHLOROQUINE (50) PREDNISONE (48) LENALIDOMIDE (42)

Which GLATIRAMER Alternatives Have Lower Bladder transitional cell carcinoma Risk?

GLATIRAMER vs GLECAPREVIR\PIBRENTASVIR GLATIRAMER vs GLEEVEC GLATIRAMER vs GLICLAZIDE GLATIRAMER vs GLIMEPIRIDE GLATIRAMER vs GLIMEPIRIDE\ROSIGLITAZONE

Related Pages

GLATIRAMER Full Profile All Bladder transitional cell carcinoma Reports All Drugs Causing Bladder transitional cell carcinoma GLATIRAMER Demographics